Clinical trial

Maridebart Cafraglutide in Heart Failure With Preserved or Mildly Reduced Ejection Fraction and Obesity

NCT07037459

StatusRECRUITING

Study typeINTERVENTIONAL

Start date2025-06-25

PhasePHASE3

Study timeline

Study start (actual)2025-06-25Date precision: day

Registry last updated2026-09-16

Observed by CureCurrent2026-10-07

Recorded dates are source observations, not predictions. Missing milestones are not estimated.

Conditions

Heart Failure With Preserved Ejection Fractionunresolved

Heart Failure With Mildly Reduced Ejection Fractionunresolved

Obesityunresolved

Interventions

Maridebart cafraglutideDRUG

PlaceboDRUG

Sponsors & collaborators

Amgenlead sponsor

Mapped research locations

BudapestHungary7 SofiaBulgaria7 AthensGreece7 PragueCzechia6 BrnoCzechia6 HoustonTexas, United States5 IstanbulTurkey (Türkiye)5 BeijingBeijing Municipality, China4 ViennaAustria4 ChangchunJilin, China4 MadridSpain3 ParisFrance3

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT07037459 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.